The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73632808" target="_blank" >RIV/61989592:15110/25:73632808 - isvavai.cz</a>

Výsledek na webu

<a href="https://link.springer.com/content/pdf/10.1007/s12672-025-03792-6.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s12672-025-03792-6.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12672-025-03792-6" target="_blank" >10.1007/s12672-025-03792-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

Popis výsledku v původním jazyce

The simultaneous occurrence of Hodgkin lymphoma (HL) and ovarian carcinoma(OC) is rare and presents unique challenges in diagnosis and treatment. Circulatingtumour DNA (ctDNA) offers a minimally invasive method for detecting minimalresidual disease in both malignancies. We present the case of a 42-year-old womanwith relapsed HL and advanced high-grade serous OC, treated with nivolumab, aPD-L1 inhibitor. After surgery and chemotherapy for OC, she received salvage therapyfor cHL, including autologous stem cell transplantation. During the therapy, thepatient was monitored using PET/CT and ctDNA analysis. CtDNA analysis detecteda Hodgkin-driven compound mutation in the STAT6 gene (N417Y/N421S) allowingearly relapse detection and treatment adjustments, detected progression of thedisease led to nivolumab initiation. The mutation was used to monitor minimalresidual disease (MRD). For ovarian carcinoma, presence of the BRAF V600E mutationas the marker was detected from archival paraffin-embedded ovarian tissue collectedat the time of diagnosis, during ctDNA monitoring, BRAF V600E associated with OCremained undetectable, aligning with remission. This case highlights the potentialof ctDNA to improve monitoring of concurrent malignancies, especially duringimmunotherapy, where PET/CT may lead to false-positive results. It is the firstreported case of nivolumab treatment for chemo-refractory relapsed HL and OC,demonstrating the utility of ctDNA in managing dual malignancies.

Název v anglickém jazyce

The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab

Popis výsledku anglicky

The simultaneous occurrence of Hodgkin lymphoma (HL) and ovarian carcinoma(OC) is rare and presents unique challenges in diagnosis and treatment. Circulatingtumour DNA (ctDNA) offers a minimally invasive method for detecting minimalresidual disease in both malignancies. We present the case of a 42-year-old womanwith relapsed HL and advanced high-grade serous OC, treated with nivolumab, aPD-L1 inhibitor. After surgery and chemotherapy for OC, she received salvage therapyfor cHL, including autologous stem cell transplantation. During the therapy, thepatient was monitored using PET/CT and ctDNA analysis. CtDNA analysis detecteda Hodgkin-driven compound mutation in the STAT6 gene (N417Y/N421S) allowingearly relapse detection and treatment adjustments, detected progression of thedisease led to nivolumab initiation. The mutation was used to monitor minimalresidual disease (MRD). For ovarian carcinoma, presence of the BRAF V600E mutationas the marker was detected from archival paraffin-embedded ovarian tissue collectedat the time of diagnosis, during ctDNA monitoring, BRAF V600E associated with OCremained undetectable, aligning with remission. This case highlights the potentialof ctDNA to improve monitoring of concurrent malignancies, especially duringimmunotherapy, where PET/CT may lead to false-positive results. It is the firstreported case of nivolumab treatment for chemo-refractory relapsed HL and OC,demonstrating the utility of ctDNA in managing dual malignancies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Discover Oncology

ISSN

2730-6011

e-ISSN

2730-6011

Svazek periodika

16

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

2054

Kód UT WoS článku

001611571200003

EID výsledku v databázi Scopus

2-s2.0-105021123812